BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
0.334
-0.211 (-38.77%)
Nov 21, 2024, 1:28 PM EST - Market open

BioLineRx Stock Forecast

BLRX's stock price has decreased by -79.99% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 2 analysts with 12-month price forecasts for BioLineRx stock have an average target of 11.5, with a low estimate of 2.00 and a high estimate of 21. The average target predicts an increase of 3,345.18% from the current stock price of 0.33.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $2.00 $11.5 $21 $21
Change +499.16% +3345.2% +6191.2% +6191.2%

Analyst Ratings

The average analyst rating for BioLineRx stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Jun '24Jul '24Aug '24Sep '24Oct '24Nov '24
Strong Buy 111222
Buy 000000
Hold 000000
Sell 000000
Strong Sell 000000
Total 111222

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$21
Strong Buy Reiterates $21 +6,191.19% Nov 6, 2024
Jones Trading
Jones Trading
Strong Buy
Initiates
$2
Strong Buy Initiates $2 +499.16% Sep 4, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$21
Strong Buy Reiterates $21 +6,191.19% Jun 3, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$21
Strong Buy Reiterates $21 +6,191.19% May 29, 2024
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$21
Strong Buy Reiterates $21 +6,191.19% Apr 17, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock

Revenue Forecast

No data available

Revenue Growth

No data available

EPS Forecast

No data available

EPS Growth

No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.